Radiopharmaceutical experts debate aggressive dosing in cancer therapy

A cadre of radiopharmaceutical researchers is pushing to expand the use of these targeted cancer therapies, arguing current clinical approaches are too conservative. The debate centers on whether higher doses or broader indications could improve efficacy, though safety and regulatory hurdles remain. This matters as radiopharmaceuticals represent a growing frontier in oncology with significant commercial and clinical implications.